Education
About Us
Working with TipRanks
Follow Us
Opus Genetics (IRD)
NASDAQ:IRD
IRD Stock Chart & Stats
$2.00
$0.08(5.63%)
At close: 4:00 PM EST
$2.00
$0.08(5.63%)
Day’s Range― - ―
52-Week Range$0.65 - $2.59
Previous CloseN/A
Volume154.21K
Average Volume (3M)431.43K
Market Cap
$137.93M
Enterprise Value$28.28M
Total Cash (Recent Filing)$30.82M
Total Debt (Recent Filing)$1.07M
Price to Earnings (P/E)―
Beta0.68
Next Earnings
May 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding68,964,210
10 Day Avg. Volume559,975
30 Day Avg. Volume431,433
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)4.73
Price to Sales (P/S)2.89
P/FCF Ratio-1.24
Enterprise Value/Market Cap0.21
Enterprise Value/Revenue1.93
Enterprise Value/Gross Profit34.49
Enterprise Value/Ebitda-0.66
Forecast
1Y Price Target
$8.00Price Target Upside300.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
ManufacturingManufacturing partnership with a major contract manufacturer reduces production risk for the LCA5 gene therapy program and supports scalability toward commercialization.
Market OpportunityAAV gene therapy portfolio targets an estimated multi‑billion dollar market in inherited retinal diseases, offering significant upside if clinical programs reach approval and capture share.
Strategic PartnershipsCollaboration with an ophthalmic partner that has prior FDA approval and positive late-stage clinical data enhances commercialization expertise and could accelerate market entry for complementary products.
Bears Say
Clinical Development RiskClinical outcomes remain uncertain as early signals from small cohorts may not replicate in larger pivotal studies, creating potential downside if efficacy or safety differs.
Financing RiskHigh development costs and cash burn could necessitate additional capital raises, which may dilute shareholders or slow program timelines if funding is not secured on favorable terms.
Regulatory UncertaintyFavorable FDA interactions do not guarantee approval or an expedited pathway, and regulatory determinations could require additional data or delay market authorization.
Opus Genetics News
IRD FAQ
What was Opus Genetics’s price range in the past 12 months?
Opus Genetics lowest stock price was $0.65 and its highest was $2.59 in the past 12 months.
What is Opus Genetics’s market cap?
Opus Genetics’s market cap is $137.93M.
When is Opus Genetics’s upcoming earnings report date?
Opus Genetics’s upcoming earnings report date is May 08, 2026 which is in 118 days.
How were Opus Genetics’s earnings last quarter?
Opus Genetics released its earnings results on Nov 12, 2025. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of -$0.13 by -$0.12.
Is Opus Genetics overvalued?
According to Wall Street analysts Opus Genetics’s price is currently Undervalued.
Does Opus Genetics pay dividends?
Opus Genetics does not currently pay dividends.
What is Opus Genetics’s EPS estimate?
Opus Genetics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Opus Genetics have?
Opus Genetics has 68,964,210 shares outstanding.
What happened to Opus Genetics’s price movement after its last earnings report?
Opus Genetics reported an EPS of -$0.25 in its last earnings report, missing expectations of -$0.13. Following the earnings report the stock price went down -2.538%.
Which hedge fund is a major shareholder of Opus Genetics?
Currently, no hedge funds are holding shares in IRD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Opus Genetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.00 (300.00% Upside)
$8.00 (300.00% Upside)
Insider Transactions
Sold Shares
Worth $8.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.3%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
47.24%
12-Months-Change
Fundamentals
Return on Equity
-338.75%
Trailing 12-Months
Asset Growth
-13.76%
Trailing 12-Months
Company Description
Opus Genetics
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.
IRD Stock 12 Month Forecast
Average Price Target
$8.00
▲(300.00% Upside)
Technical Analysis
Ownership Overview
16.15% Insiders
2.10% Mutual Funds
23.58% Other Institutional Investors
56.04% Public Companies and Individual Investors
Options Prices
Currently, No data available
---